Lunit Inc.

Equities

A328130

KR7328130000

Advanced Medical Equipment & Technology

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
53,800 ^KRW	+1.89%		+7.17%	-34.31%

Apr. 16	Lunit Wins Shareholder Approval for Volpara Health Takeover	MT
Apr. 12	Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover	MT

Lunit Inc. announced that it has received KRW 59.887912282 billion in funding from a group of investors

July 18, 2021

On July 19, 2021, Lunit Inc. closed the transaction. The company has received KRW 29,887.912282 million in its second tranche from new investor, Guardant Health, Inc. The company has received KRW 59,887.912282 million in the transaction.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	NH INVESTMENT & SECURITIES CO., LTD.	11,720 KRW	+0.43%	+6.64%	2.93B
	GUARDANT HEALTH, INC.	18.1 USD	+4.38%	+10.43%	2.11B

Latest news about Lunit Inc.

Lunit Wins Shareholder Approval for Volpara Health Takeover	Apr. 16	MT
Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover	Apr. 12	MT
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals	Apr. 08	CI
Lunit Announces Publication of New Study Featuring Lunit SCOPE IO	Mar. 26	CI
Lunit Announces Two Commercial Deals Signal its Expansion in Europe	Mar. 18	CI
Lunit Inc. Receives Two Supply Contracts That Mark Its Strategic Expansion into the East and Southeast Asian Region	Mar. 11	CI
Lunit Announces Three-Year Supply Contract with Samsung Electronics	Jan. 16	CI
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment	Dec. 26	MT
Lunit to Take Over Volpara Health; Lunit Shares Decline 4%	Dec. 15	MT
Lunit Inc. agreed to acquire Volpara Health Technologies Limited from Harbour Asset Management Limited and others for AUD300 million.	Dec. 12	CI
Lunit Inc. Partners with NTT DATA Singapore to Introduce Lunit Insight CXR to Singapore's Public Healthcare System	Nov. 30	CI
Lunit Unveils Prognostic Insights for Colon Cancer - Published in Npj Precision Oncology	Nov. 27	CI
Lunit Announces to Unveil Eight Groundbreaking Abstracts At the Radiological Society of North America	Nov. 20	CI
Lunit Inc. Receives U.S. Food and Drug Administration 510(K) Clearance for its 3D Breast Tomosynthesis Ai Solution, Lunit Insight DBT	Nov. 14	CI
Lunit Expands Reach of Its AI-Powered Chest Screening Solution to Global Military Health Institutions	Nov. 09	CI
Lunit Inc. Announces Collaborative Study with the Samsung Medical Center Assessed Tumor-Infiltrating Lymphocytes	Nov. 01	CI
Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy	23-10-27	CI
New Study Demonstrates Lunit Inc. Scope Io's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to Be Presented At the ESMO 2023	23-10-16	CI
Lunit Presents Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer	23-08-01	CI
Blackford and Lunit Inc Announce Partnership to Enhance Chest and Breast Ai Solution Offering	23-07-27	CI
Lunit Accelerates Expansion Across Middle East by Bringing AI Solution to Dr. Sulaiman Al Habib Medical Group	23-07-26	CI
Lunit Makes Full-Fledged Entry into the Middle East with Participation in 'Saudi Vision 2030' Healthcare Transformation Project	23-07-05	CI
Lunit and Capio S:t Gran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis	23-06-05	CI
Lunit Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Lunit and Agfa Announces Lunit Insight Cxr's Integration in Agfa's Musica® Workstation; Demonstration and Presentation to Be Showcased At Ecr 2023	23-02-27	CI

Chart Lunit Inc.

Duration

Period

More charts

Company Profile

Lunit Inc is a Korea-based company principally engaged in the development and supply of medical software. The Company is principally engaged in the development and supply of medical software such as cancer diagnostic aid solutions, cancer early detection solutions, cancer risk prediction solutions and others through artificial intelligence (AI) technologies.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-10 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lunit Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

53,800 KRW

Average target price

100,000 KRW

Spread / Average Target

+85.87%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Medical Software & Technology Services

	1st Jan change	Capi.
LUNIT INC.	-34.31%	1.11B
VEEVA SYSTEMS INC.	+4.16%	32.45B
PRO MEDICUS LIMITED	+12.62%	7.26B
SECTRA AB	+20.83%	3.84B
EVOLENT HEALTH, INC.	-11.41%	3.43B
OMNICELL, INC.	-27.11%	1.31B
SIMULATIONS PLUS, INC.	+4.25%	919M
VERADIGM INC.	-23.45%	856M
B-SOFT CO.,LTD.	-38.17%	840M
SURGICAL SCIENCE SWEDEN AB	-17.86%	712M

Medical Software & Technology Services